ACT-AD Urges Bi-partisan Legislation to Exempt FDA User Fees from Sequestration
ACT-AD Chairman Daniel Perry urges House and Senate Budget Committee leaders to take action on bi-partisan legislation to exempt FDA user fees from sequestration. The letters convey the importance of the user fee programs in funding timely and predictable drug, device, and biologic review activities and also describes how the FDA has been trying to maintain their direct review activities and pursue many of the exciting new initiatives included in the most recent authorizations of the prescription drug and medical device user fee programs, without collecting the full fees planned for this year.
View House Letter
View Senate Letter